Reading the tape
NASDAQ: NUVL
Nuvalent, Inc.
Healthcare · Biotechnology
Market Cap
$7.55B
52w High
$113.02
52w Low
$63.56
P/E
-18.12
Volume
554.45K
Outstanding Shares
73.54M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 36.05%FCF (TTM): -48.71%
What changed
The stock rose 36.05% over the last year. Free cash flow declined 48.71% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer.
CEOJames R. Porter
SectorHealthcare
IndustryBiotechnology
Employees162
IPO dateJul 29, 2021
Valuation
Forward P/E—
EV/EBITDA-672.36
Enterprise value$7.05B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-34.08%▼39.80%vs FY2024
Analyst consensus
RatingBuy
Target price$144.40▲40.71%
14
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$1.35 · Revenue est $486K
View